Mimedx Group, INC 8-K filings

MiMedx Group, Inc. has entered into a merger agreement with Sanara MedTech Inc., combining operations in a strategic move to enhance market presence and product offerings.

MiMedx Group announced Q2 2026 results with net sales of $64 million, down 35% year-over-year, while simultaneously revealing plans to acquire Sanara MedTech for approximately $350 million.

MiMedx Group, Inc. announced its definitive agreement to acquire Sanara MedTech Inc. for approximately $350 million in a cash and stock transaction, aiming to expand its surgical footprint and regenerative medicine offerings.

MiMedx Group held its 2026 Annual Meeting, re-electing directors, approving executive compensation, and ratifying auditor appointment, alongside a bylaw amendment.

MiMedx Group, Inc. reported a significant decline in first-quarter net sales due to new Medicare reimbursement policies impacting its Wound business, while its Surgical segment showed strong growth.

MiMedx Group is eliminating the COO role and reducing executive salaries as part of a $40 million annual cost-cutting initiative.

MiMedx Group, Inc. announced record operating and financial results for the fourth quarter and full year 2025, alongside a new $100 million share repurchase authorization.

MIMEDX Group, Inc. updated its investor presentation on January 12, 2026, outlining strategic priorities, financial highlights, and growth opportunities in wound and surgical markets.

MiMedx Group, Inc. announced record net sales, Adjusted EBITDA, and cash flow for the third quarter of 2025, leading to an increased full-year financial outlook.

MIMEDX Group, Inc. updated its investor presentation for the Cantor Global Healthcare Conference, highlighting strategic priorities and growth expectations.

MIMEDX Group, Inc. reported record second-quarter 2025 net sales of $99 million, a 13% year-over-year increase, and raised its full-year net sales growth expectations to low double-digits.

MIMEDX Group, Inc. announced that its shareholders re-elected all nine directors, approved executive compensation, ratified Deloitte & Touche LLP as auditor, and amended the 2016 Equity and Cash Incentive Plan at its 2025 Annual Meeting.

MiMedx Group, Inc. provides an updated investor presentation highlighting its growth strategy, product portfolio, and financial performance at the Bank of America Securities 2025 Healthcare Conference.

MiMedx Group, Inc. announced a 4% year-over-year increase in net sales for Q1 2025, reaching $88 million, and reaffirmed its 2025 financial outlook despite delays in Medicare reform.

MiMedx Group announces positive 2024 financial results and outlines strategic priorities for 2025, including expanding its surgical footprint and capitalizing on favorable reimbursement trends.

MiMedx Group announces a 7% year-over-year increase in net sales for Q4 2024 and a 9% increase for the full year, alongside a 21% Adjusted EBITDA margin for the quarter.

MiMedx Group, Inc. updates its investor presentation, outlining its strategic priorities for 2025 and beyond, focusing on innovation, market expansion, and financial performance.

MiMedx Group, Inc. has extended its corporate headquarters lease for an additional three years and approved new indemnification agreements for its directors and executive officers.

MiMedx Group presented its strategic priorities, product portfolio, and market opportunities at recent healthcare conferences, highlighting its focus on wound and surgical solutions.

MiMedx Group, Inc. announced a 3% year-over-year increase in net sales for the third quarter of 2024, along with an adjusted EBITDA margin of 22%, and raised its full-year net sales growth expectations.

MiMedx announced a 7% year-over-year increase in net sales to $87 million and an adjusted EBITDA of $20 million for the second quarter of 2024, despite facing competitive pressures.

MiMedx Group successfully held its 2024 Annual Meeting, re-electing all nine directors, approving executive compensation, and ratifying Deloitte & Touche LLP as its auditor for the fiscal year ending December 31, 2024.

MiMedx Group, Inc. announced a robust first quarter of 2024, highlighted by an 18% year-over-year increase in net sales and significant improvements in profitability.

MiMedx is challenging the FDA's decision that Axiofill does not qualify as a Human Cell, Tissue or Cellular or Tissue-based Product (HCT/P) and has filed a lawsuit while maintaining its 2024 financial guidance.

MiMedx Group, Inc. has appointed Tiffany Olson and Dorothy Puhy as new independent directors, effective March 1, 2024, increasing the board size to eleven members.

MiMedx Group, Inc. announced a 17% increase in fourth-quarter net sales and a 20% increase for the full year 2023, alongside significant improvements in profitability and cash flow.

MiMedx has refinanced its existing debt and secured a new $95 million credit facility, improving its capital structure and providing additional financial flexibility.